中重度特应性皮炎系统治疗的比较疗效与安全性:系统文献综述与网状Meta分析
本网状Meta分析纳入19项截至2019年10月24日发表的随机对照试验,比较abrocitinib、baricitinib、dupilumab等系统治疗中重度特应性皮炎的短期疗效与安全性。单药治疗中upadacitinib 30 mg QD的EASI-50应答率数值最高(83.6%),联合治疗中abrocitinib 200 mg QD最高(86.6%)。各活性治疗间治疗中出现的不良事件无显著差异。
要点
- 单药治疗中upadacitinib 30 mg QD的EASI-50应答率数值最高(83.6%)。
- 联合治疗中abrocitinib 200 mg QD的EASI-50应答率最高(86.6%)。
- 各活性治疗间治疗中出现的不良事件无显著差异。
核心结论
- 在成人和青少年特应性皮炎患者中,abrocitinib、dupilumab和upadacitinib始终是最有效的系统治疗,短期随机对照试验中治疗中出现的不良事件无显著差异。
研究设计与样本
- 系统文献综述纳入2019年10月24日前发表的19项2期和3期随机对照试验,涉及abrocitinib、baricitinib、dupilumab、lebrikizumab、nemolizumab、tralokinumab和upadacitinib。
- 对单药治疗和联合治疗(系统治疗联合外用抗炎治疗)的短期(12-16周)疗效、患者报告结局和安全性数据分别进行固定效应和随机效应贝叶斯网状Meta分析。
主要发现
- 单药治疗随机对照试验中,upadacitinib 30 mg每日一次(QD)的EASI-50应答率数值最高(83.6%),其次为abrocitinib 200 mg QD(74.6%)、upadacitinib 15 mg QD(70.5%)、dupilumab 300 mg每2周一次(Q2W)(63.4%)和abrocitinib 100 mg QD(56.7%)。
- EASI-75和EASI-90应答率呈现相似趋势,IGA应答和患者报告结局也观察到相似结果。
- 联合治疗随机对照试验中,abrocitinib 200 mg QD的EASI-50应答率最高(86.6%),其次为dupilumab 300 mg Q2W(82.4%)和abrocitinib 100 mg QD(79.7%)。
- 在单药和联合治疗随机对照试验中,所有活性治疗的治疗中出现的不良事件概率均高于安慰剂,但联合治疗中dupilumab 300 mg Q2W(OR 0.96,95% CrI 0.45-2.18)和abrocitinib 100 mg QD(OR 0.95,95% CrI 0.35-2.66)除外;活性治疗之间无显著差异。
关键数值与推荐
- 单药治疗中upadacitinib 30 mg QD的EASI-50应答率为83.6%,abrocitinib 200 mg QD为74.6%,upadacitinib 15 mg QD为70.5%,dupilumab 300 mg Q2W为63.4%,abrocitinib 100 mg QD为56.7%。
- 联合治疗中abrocitinib 200 mg QD的EASI-50应答率为86.6%,dupilumab 300 mg Q2W为82.4%,abrocitinib 100 mg QD为79.7%。
- 联合治疗中dupilumab 300 mg Q2W的治疗中出现的不良事件OR为0.96(95% CrI 0.45-2.18),abrocitinib 100 mg QD的OR为0.95(95% CrI 0.35-2.66)。
临床怎么用
- 对于中重度特应性皮炎的成人和青少年患者,可参考本网状Meta分析结果选择系统治疗,abrocitinib、dupilumab和upadacitinib显示较高疗效。
- 临床决策时需结合短期疗效数据与安全性信息,注意活性治疗的不良事件概率总体上高于安慰剂。
局限性
- 纳入的随机对照试验仅发表于2019年10月24日之前,未涵盖更近期的研究。
- 分析基于短期(12-16周)数据,缺乏长期疗效和安全性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given the lack of head-to-head studies of systemic therapies in moderate-to-severe atopic dermatitis (AD), network meta-analyses (NMAs) can provide comparative efficacy and safety data to inform clinical decision-making. In this NMA, eligible randomized controlled trials (RCTs) published before 24 October 2019 were identified by a systematic literature review. Short-term (12-16 weeks) efficacy (Investigator's Global Assessment [IGA] and Eczema Area and Severity Index [EASI] responses), patient-reported outcomes (PROs) and safety data from each trial were abstracted and analysed separately for monotherapy and combination therapy (systemic plus topical anti-inflammatory therapy). RCTs were analysed in fixed-effects and random-effects Bayesian NMA models. Overall, 19 phase 2 and phase 3 RCTs of abrocitinib, baricitinib, dupilumab, lebrikizumab, nemolizumab, tralokinumab and upadacitinib were included. In monotherapy RCTs, upadacitinib 30 mg once daily (QD) had the numerically highest efficacy (83.6% achieved ≥50% improvement in EASI [EASI-50 response]), followed by abrocitinib 200 mg QD (74.6%), upadacitinib 15 mg QD (70.5%), dupilumab 300 mg every 2 weeks (Q2W) (63.4%) and abrocitinib 100 mg QD (56.7%). Similar trends in EASI-75 and EASI-90 response were observed. In combination therapy RCTs, abrocitinib 200 mg QD had the highest EASI-50 (86.6%), followed by dupilumab 300 mg Q2W (82.4%) and abrocitinib 100 mg QD (79.7%). Similar findings were observed for IGA response and PROs. In monotherapy and combination therapy RCTs, the probability of treatment-emergent adverse events (TEAEs) was higher among all active treatments than with placebo (except for dupilumab 300 mg Q2W [odds ratio (OR), 0.96; 95% credible interval (CrI), 0.45-2.18] and abrocitinib 100 mg QD [OR, 0.95; 95% CrI, 0.35-2.66] in combination therapy RCTs), although active treatments did not significantly differ from one another. Abrocitinib, dupilumab and upadacitinib were consistently the most effective systemic therapies in adult and adolescent patients with AD, with no significant TEAE differences in short-term RCTs.
引用
- Silverberg JI, Thyssen JP, Fahrbach K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021. PMID: 33991374. doi:10.1111/jdv.17351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。